RO-0622
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- RO-0622
- Molecular weight
- 286.22
- Structure (SMILES)
These details could not be displayed.
- azvudine
- Azvudine
- AZVUDINE
- Azvudine [WHO-DD]
- Azvudine tablets
- Azvudine tablets(FNC)
- azvudine who dd
- fnc
- FNC
- ro 0622
- RO 0622
- Ro-0622
- CAS registry numbers
- 1011529-10-4
- ChEMBL ID
- CHEMBL519846
- InChIKey
- KTOLOIKYVCHRJW-XZMZPDFPSA-N
- FDA ingredient codes (UNII)
- IJ2XP0ID0K
- 24769759
- 163325167
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- azvudine
- Type
- Synthetic organic
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Protein identifier
- Q72547
- Mechanism
- Replicase polyprotein 1ab inhibitor
- Action type
- Inhibitor
- Target
- Replicase polyprotein 1ab
- Protein identifier
- P0DTD1
- Mechanism
- Reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Reverse transcriptase
- Protein identifier
- Q06347
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Replicase polyprotein 1ab inhibitor
- Action type
- Inhibitor
- Target
- Replicase polyprotein 1ab
- Mechanism
- Reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Reverse transcriptase
Investigated indications
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT04668235
- NCT05033145
- NCT05633433
- NCT05682599
- NCT05689034
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 3
- Polar surface area
- 159.36
- Calculated partition coefficient (ALogP)
- -0.95
- Calculated partition coefficient (XLogP)
- -0.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 20
- Molecular formula
- C9H11FN6O4
- Monoisotopic mass
- 286.08258102
- Natural product
- No
- Recorded assays
- 75
- Active assays
- 20
Active assay types
- Confirmatory
Related records
Trials (23)
- [14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Itraconazole Capsules (ICZ)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV)
- A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)
- A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）
- A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects
- A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B
- A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection
- A Study to Evaluate the Pharmacokinetics and Safety of Azvudine Tablets in Healthy Adult Subjects and Healthy Elderly Subjects
- An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia
- Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China
- Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19
- Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness
- Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients
- Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients
- Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study
- Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)
In development for (1)
- COVID-19 Phase 3